Immuneering Corporation Financing Cash Flow
Immuneering Corporation (IMRX) reported Financing Cash Flow of $205.37 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Immuneering Corporation net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $24.61K.
- Immuneering Corporation net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $180.76K, a 98.69% decline year-over-year.
- Immuneering Corporation net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$357.52K.
- Immuneering Corporation net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $213.19M, a 4784.59% increase year-over-year.
- Immuneering Corporation net cash provided by (used in) financing activities for fiscal 2025 was $226.58M, a 4172.32% increase from fiscal 2024.
- Immuneering Corporation net cash provided by (used in) financing activities for fiscal 2024 was $5.30M, a 81.35% decline from fiscal 2023.
- Immuneering Corporation net cash provided by (used in) financing activities for fiscal 2023 was $28.44M, a 149558.35% increase from fiscal 2022.
- Immuneering Corporation net cash provided by (used in) financing activities for fiscal 2022 was $19.00K, a 99.99% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $205.37K 10-Q · filed 2026-08-05 | -$152.16K derived: sum of 3 quarters · filed 2026-08-05 | $213.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $180.76K 10-Q · filed 2026-05-15 | -$176.76K derived: sum of 2 quarters · filed 2026-05-15 | $213.02M derived: sum of 3 quarters · filed 2026-05-15 | $212.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$357.52K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $212.83M derived: sum of 2 quarters · filed 2026-03-06 | $212.77M derived: sum of 3 quarters · filed 2026-08-05 | $226.58M 10-K · filed 2026-03-06 |
| 2025-09-30 | $213.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $213.13M derived: sum of 2 quarters · filed 2026-08-05 | $226.94M 10-Q · filed 2025-11-12 | $226.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$61.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $13.75M 10-Q · filed 2026-08-05 | $13.71M derived: sum of 3 quarters · filed 2026-08-05 | $18.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $13.81M 10-Q · filed 2026-05-15 | $13.77M derived: sum of 2 quarters · filed 2026-05-15 | $18.13M derived: sum of 3 quarters · filed 2026-05-15 | $18.13M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$40.99K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $4.32M derived: sum of 2 quarters · filed 2026-03-06 | $4.32M derived: sum of 3 quarters · filed 2026-03-06 | $5.30M 10-K · filed 2026-03-06 |
| 2024-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.36M derived: sum of 2 quarters · filed 2025-11-12 | $5.34M 10-Q · filed 2025-11-12 | $5.35M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $979.92K 10-Q · filed 2025-08-13 | $987.76K derived: sum of 3 quarters · filed 2025-08-13 | $1.01M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $979.92K 10-Q · filed 2025-05-05 | $987.76K derived: sum of 2 quarters · filed 2025-05-05 | $1.01M derived: sum of 3 quarters · filed 2025-05-05 | $29.18M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $7.83K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $29.28K derived: sum of 2 quarters · filed 2025-03-20 | $28.20M derived: sum of 3 quarters · filed 2025-03-20 | $28.44M 10-K · filed 2025-03-20 |
| 2023-09-30 | $21.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $28.19M derived: sum of 2 quarters · filed 2024-11-13 | $28.43M 10-Q · filed 2024-11-13 | $28.25M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $28.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $28.41M 10-Q · filed 2024-08-06 | $28.23M derived: sum of 3 quarters · filed 2024-08-06 | $28.21M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $239.41K 10-Q · filed 2024-05-07 | $54.73K derived: sum of 2 quarters · filed 2024-05-07 | $37.52K derived: sum of 3 quarters · filed 2024-05-07 | $65.30K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$184.68K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$201.89K derived: sum of 2 quarters · filed 2024-03-01 | -$174.11K derived: sum of 3 quarters · filed 2024-03-01 | $19.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | -$17.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $10.57K derived: sum of 2 quarters · filed 2023-11-09 | $203.68K 10-Q · filed 2023-11-09 | $211.20K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $27.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $220.90K 10-Q · filed 2023-08-03 | $228.41K derived: sum of 3 quarters · filed 2023-08-03 | $118.72M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $193.11K 10-Q · filed 2023-05-04 | $200.63K derived: sum of 2 quarters · filed 2023-05-04 | $118.69M derived: sum of 3 quarters · filed 2023-05-04 | |
| 2021-12-31 | $7.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $118.50M derived: sum of 2 quarters · filed 2023-03-06 | $144.26M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $118.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $144.26M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $25.77M 10-Q · filed 2022-08-10 | |||
| 2020-12-31 | $36.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $36.98M derived: sum of 2 quarters · filed 2022-03-10 | $37.98M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $998.31K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $998.31K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |